


Kidney News

February 2015 | Vol. 7, Number 2

Small Changes in Blood Acidity May Affect CKD Patients' Health



Very small changes in pH levels in the blood may affect renal calcium reabsorption and parathyroid hormone (PTH) secretion, new research suggests. The findings, which are published in the *Journal of the American Society of Nephrology*, could have important implications for the health of patients with chronic kidney disease (CKD).

"In CKD, calcium and phosphate lost from the bone can end up in the walls of the blood vessels and in other soft tissues, causing potentially serious complications," said senior author Donald Ward, PhD, of the University of Manchester, in the UK. "The key protein that controls our blood calcium levels is the calcium-sensing receptor, and what we have found is that the mild acidity, or acidosis, that is often seen in CKD is sufficient to impair this protein from working properly."

In their efforts to uncover the health effects that patients with CKD experience due to the excess release of calcium and phosphate from the bones, Ward and his team found that in both human embryonic kidney cells and bovine parathyroid cells, slightly decreasing the extracellular pH from 7.4 to 7.2 rapidly inhibited intracellular calcium mobilization through the calcium-sensing receptor, whereas raising extracellular pH to 7.6 increased responsiveness to extracellular calcium. "It was known before that large changes in acidity—larger than would normally be seen in human blood—could affect calcium-sensing receptor activity," Ward said. However, what we have found

here is that even relatively mild increases in blood acidity, similar to those commonly seen in CKD, could also inhibit the receptor in cell experiments in our laboratory."

Also, pH elevation suppressed PTH secretion from human parathyroid cells, while acidosis increased PTH secretion. The findings suggest that acid-base disturbances may affect the control of parathyroid function and calcium metabolism. While other pH-sensitive membrane proteins may also be involved, the extracellular pH changes had no effect in cells lacking the calcium-sensing receptor, or incubated in low extracellular concentrations of calcium.

Because metabolic acidosis and secondary hyperparathyroidism are both common consequences of CKD, the study's results point to a mechanistic link between the two. Also, the observation that raising extracellular pH promotes calcium-sensing receptor-mediated suppression of PTH secretion points to a new therapeutic strategy for treating secondary hyperparathyroidism in CKD.

"Past studies showed that extracellular pH is capable of affecting calcium-sensing

Continued on page 6

CKD Prevalence Stable, but Higher in Older Adults, Report Says

The US prevalence of end stage renal disease (ESRD) continues to increase, but the rate of new cases may be leveling off. Meanwhile, mortality among patients on dialysis or with a kidney transplant continues to de-

cline. Those are among the key findings of the recently released 2014 US Renal Data System Annual Data Report.

The report also finds that the prevalence of chronic kidney disease (CKD) has remained relatively stable, but con-

tinues to increase in the Medicare population. The 2014 report on the "state of kidney disease" in the United States was released by the US Renal Data System (USRDS) Coordinating Center, based at the University of Michigan in partnership with Arbor Research Collaborative for Health. Rajiv Saran, MD, is director of the USRDS Coordinating Center and associate director of the University of Michigan's Epidemiology and Cost Center.

Continued on page 2

Inside

Maintenance of Certification

ABIM shifts course; will engage medical community on MOC

Journal View

Early adopters of surgical robots have greater success in partial nephrectomy

Nephrology Fellow Survey


Among the findings: 43% of nephrology fellows looking for employment reported changing their plans because of limited practice opportunities

Detective Nephron

One electrolyte disorder in a patient with ESRD nets a systemic diagnosis

World Kidney Day 2015

Themed "Kidney Health for All," WKD highlights CKD challenges such as poor water, unhealthy food and beverage choices, and literacy



CKD Prevalence Stable

Continued from page 1

CKD remains stable, but higher in older adults

The USRDS is a national data system that collects, analyzes, and distributes information on kidney disease trends. Based on data from the National Health and Nutrition Examination Survey (NHANES), the report suggests an overall CKD prevalence of 13.6 percent.

Saran noted that while CKD prevalence was “certainly stable” during the periods 1999–2004 and 2007–2012, it was about 30 percent higher than in the 1988–1994 NHANES cohort.

“It’s 13.6%, which is a pretty high prevalence,” he said in an interview. “Let’s say conservatively even if it’s 12% . . . that is still higher than the prevalence of diabetes in the general population. That fact is not well-recognized.”

Medicare data suggest an ongoing increase in CKD among Americans aged 65 years or older. In 2012, the most recent year for which data were available, the prevalence of recognized CKD in the Medicare population was 10.4 percent.

That is consistent with recent evidence suggesting that age may be the single strongest risk factor for CKD. “When we look at the risk factors for CKD, we look at diabetes, we look at hypertension, we look at BMI/obesity, the one thing that sticks out and has the highest odds ratio in terms of the strength of that relationship is age,” Saran said. The growing body of evidence on CKD and age has “practical implications for screening, prevention, risk stratification, and treatment,” according to the USRDS report. “Another point I’d like to make is, the prevalence of urine testing leaves a lot to be desired,” Saran added. “Even in the Medicare data, only about 40 percent of diabetics are receiving the urine test. So it tells you that there’s still lots of room for improvement, even among those that have clear-cut, known risk factors.”

Although care patterns are difficult to assess, data suggest that while 91 percent of Medicare patients with CKD see a primary care physician and 62 percent see a cardiologist within a year of diagnosis, only 31 percent see a nephrologist. For patients with stage 3 to 5 CKD, the rate of nephrologist care increases to 55 percent.

All-cause mortality continues to decline among Medicare patients with CKD. But these patients remain at much higher risk of death than those without CKD, a risk that is “multiplied” for CKD patients with cardiovascular disease or diabetes. Cardiovascular morbidity remains very high among Medicare patients with CKD—about 70 percent, compared to 35 percent in patients without CKD.

The report also highlights the ongoing, age-related increase in hospitalizations for acute kidney injury (AKI)—a diagnosis associated with declines in both renal and functional status. Less than 20 percent of patients see a nephrologist within one year of AKI hospitalization, even though more

than 90 percent undergo follow-up serum creatinine testing.

Continued declines in ESRD incidence

For the third consecutive year, new cases of ESRD declined, with 114,813 new cases in 2012. In that year, the adjusted incidence rate was 353 per million per year—the lowest since 1997.

The population prevalence of ESRD continued to increase, although there were encouraging signs that the rate of growth may be slowing. “[T]he percentage increase in 2011 and

2012 was the lowest recorded over the last three decades,” according to the USRDS report. At the end of 2012, there were a total of 636,905 dialysis and transplant patients receiving treatment for ESRD.

Analysis of Healthy People 2020 goals showed that about one-third of patients see a nephrologist at least one year before the start of renal replacement therapy. Nearly all mortality targets have been met, including promising trends in overall and cardiovascular mortality among dialysis and transplant patients.

Clinical indicators of hemodialysis care are also improving—nearly 80 percent of

patients now have an arteriovenous fistula or graft during the first year. Mean hemoglobin levels have declined, reflecting changes in erythropoietin use. Although mortality rates continue to decline, they are up to eight times higher than for matched Medicare patients without ESRD.

Transplantation rates have decreased, while the percentage of dialysis patients wait-listed continues to increase. In 2012, nearly 29,000 patients were added to transplant waiting lists. For those who do receive a transplant, one-year survival rates are excellent: 96 percent for deceased donor transplant recipients, and 99 percent

TINY CRYSTALS. BIG PROBLEM.



References:

1. Dalbeth N, Stamp L. Hyperuricaemia and gout: time for a new staging system? *Ann Rheum Dis*. 2014;73(9):1598-1600.
2. Paparo F, Zampogna G, Fabbro E, et al. Imaging of tophi with an extremity-dedicated MRI system. *Clin Exp Rheumatol*. 2011;29(3):519-526.
3. Schumacher HR Jr. The pathogenesis of gout. *Cleve Clin J Med*. 2008;75(suppl 5):S2-S4.
4. Taylor JW, Grainger R. Clinical features of gout. In: Terkeltaub R (ed). *Gout and Other Crystal Arthropathies*. 1st ed. Philadelphia, PA: Elsevier Saunders; 2012:105-120.
5. Terkeltaub R, Edwards NL. Disease definition and overview of pathogenesis of hyperuricemia and gouty inflammation. In: Terkeltaub R, Edwards NL (eds). *Gout: Diagnosis and Management of Gouty Arthritis and Hyperuricemia*. 3rd ed. Durant, OK: Professional Communications, Inc; 2013:19-47.

for living donor transplant recipients.

The incidence of pediatric ESRD remained stable, with 1161 cases in 2012. At the end of that year, nearly three-fourths of children with ESRD had a functioning kidney transplant.

Can nephrologists help keep the trends going?

The slow but steady decline in ESRD is encouraging news, Saran said. "But the question is what's causing [it] and can we accelerate that?" Noting that more in-depth studies are planned, he speculated on some

possible reasons.

Increased recognition of CKD. "Certainly by claims, we notice that there is greater recognition of CKD in the health systems, by providers," Saran said. He said near-universal eGFR reporting has been an important contributor to the increased recognition of CKD. "There's better care of CKD, and there's better detection and care of upstream CKD risk factors such as diabetes and hypertension," Saran said. "So there may be a slower progression of CKD overall. Over time, perhaps, CKD in general is progressing slower, so people are not reaching ESRD as quickly as they used to in

different settings."

Changes in risk factors. Saran also noted improvement in risk factor profiles nationwide, including stabilization of obesity rates and reduction in cardiovascular mortality.

Starting dialysis later. "In recent years there has been some evidence that earlier start to dialysis is not that advantageous, as some physicians had long believed," said Saran. So it could be that nephrologists may be starting dialysis "a little bit later." If so, "that could somewhat artificially lower the incidence of ESRD."

What can nephrologists do to keep that trend going? "Raising awareness, raising

the ante for upstream CKD, earlier stages of CKD, and improving the recognition, awareness, management, continuing to harp on the importance of recognizing CKD earlier and earlier . . . should be the mantra to be followed communitywide," Saran said. "The other thing is lifestyle factors. I'm going really upstream now. As a community, nephrologists have to be more and more in favor of practicing lifestyle medicine. They need to be part of that. They can't take care of all the CKD that there is, so I think they have to advise, guide, and work with their primary and other colleagues. ●



For many patients with gout, emerging science suggests that chronically elevated sUA and the resulting monosodium urate crystal deposition can be more serious and widespread in the body than we ever thought, leaving inflammation, bone erosion, and organ damage in its wake.¹⁻⁵

Isn't it time to take a deeper look at gout?

AstraZeneca 

©2015 AstraZeneca. All rights reserved. 3082709 1/15



Kidney Health for All

World Kidney Day kicks off on Thursday, March 12, with the theme "Kidney Health for All." This year's theme, on the 10th anniversary of WKD, recognizes that not everyone is equal with regard to risk for kidney disease and access to treatment.

African American, American Indian, Hispanic, Asian and Aboriginal populations are known to suffer from higher rates of diabetes and high blood pressure, which are both leading causes for CKD.

CKD is often difficult to prevent and treat in these populations owing to poor water hygiene, lack of hydration, unhealthy food and beverages, literacy levels, and lack of adequate health insurance. WKD highlights the importance of water to kidney health with the campaign, "Drink a Glass of Water and Give One Too." Just drink a glass of water, take a picture, and share: Today I celebrate #worldkidneyday. I drink and give a #glassofwater because #Isupport wkd.

For more information, visit www.worldkidneyday.org





KidneyNews

Editorial Staff

Editor-in-Chief: Richard Lafayette, MD, FACP

Executive Editor: Dawn McCoy

Content and Media Analyst: Kurtis Pivert

Design: Lisa Cain Design

Communications Assistant: Sara Leeds

Editorial Board:

Joseph Mattana, Winthrop University Hospital, New York, NY

Linda McCann, RD, RCN, Satellite Dialysis, San Jose, CA

Andrew King, MD, Scripps, San Diego, CA

Pascale Lane, MD, FASN, University of Oklahoma Health Sciences

Edgar V. Lerma, MD, FASN, University of Illinois – Chicago /Associates in Nephrology, SC

Glenda Payne, MS, RN, CNN, Nephrology Clinical Solutions

Jeffrey Petersen, MD, Amgen

Amy Williams, MD, Mayo Clinic, Rochester, MN

Advertising Sales:

The Walchli Tauber Group

2225 Old Emmorton Road, Suite 201, Bel Air, MD 21015

443-252-0571 Mobile

443-512-8899 *115 Phone

christine.kenney@wt-group.com

ASN Council:

President: Jonathan Himmelfarb, MD, FASN

President-elect: Raymond C. Harris, MD, FASN

Past-President: Sharon M. Moe, MD, FASN

Secretary-Treasurer: John R. Sedor, MD, FASN

Communications Committee Chair: Eleanor D. Lederer, MD, FASN

Councilors: Eleanor D. Lederer, MD, FASN, Mark D. Okusa, MD, FASN,

Mark E. Rosenberg, MD, FASN, Anupam Agarwal, MD, FASN

Executive Director: Tod Ibrahim

Director of Communications: Robert Henkel

ASN Kidney News is published by the American Society of Nephrology
1510 H Street NW, Suite 800, Washington, DC 20005. Phone: 202-640-4660

www.asn-online.org

ASN Kidney News is the authoritative source for analysis of trends in medicine, industry, and policy affecting all practitioners in nephrology. The statements and opinions expressed in *ASN Kidney News* are solely those of the authors and not of the American Society of Nephrology (ASN) or the editorial policy of the editors. The appearance of advertisements in *ASN Kidney News* is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality, or safety. The American Society of Nephrology disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the articles or advertisements.

The American Society of Nephrology is organized and operated exclusively for scientific and educational purposes, including enhancing the field of nephrology by advancing the scientific knowledge and clinical practice of that discipline through stimulation of basic and clinical investigation, providing access to new knowledge through the publication of journals and the holding of scientific meetings, advocating for the development of national health policies to improve the quality of care for renal patients, cooperating with other national and international societies and organizations involved in the field of nephrology, and using other means as directed by the Council of the Society.

Postmaster: Please send address changes to *ASN Kidney News*, c/o Customer Service, American Society of Nephrology 1510 H Street NW, Suite 800, Washington, DC 20005.

Publications mail agreement No. 40624074. Return undeliverable Canadian addresses to PO Box 503, RPO West Beaver Creek, Richmond Hill ON L4B 4R6

ASN Kidney News (ISSN print 1943-8044 and online 1943-8052) is an official publication of the American Society of Nephrology, 1510 H Street NW #800, Washington DC 20005, and is published monthly. Periodicals postage paid at Washington, DC and at additional mailing offices. Subscription rates: \$12 per year. To order, please email bhenkel@asn-online.org. Subscription prices subject to change. Annual ASN membership dues include \$12 for *ASN Kidney News* subscription.

Copyright© 2015 All rights reserved



Corporate Supporters

The ASN Corporate Support Program recognizes supporters year round for their generous contributions to the Society. Through this program, supporters help ASN lead the fight against kidney disease. ASN gratefully acknowledges the following companies for their contributions in 2014.

Diamond Level



Platinum Level





**Registration
CLOSES SOON!**

ASN Highlights US

Translating Kidney Week into Clinical Practice

ASN Highlights is a clinically focused educational opportunity, translating Kidney Week 2014 into practical advice with clinical relevance. The new ASN Highlights format is designed to help you incorporate the best of Kidney Week into patient care.

Why Attend?

- 7.5 CME credits
- Meet-the-Expert Roundtables
- Panel Discussions & Debates
- Networking with local colleagues

Topics Include:

- AKI
- ESRD
- General Nephrology & CKD
- Glomerular Diseases
- Hypertension
- Transplantation

Three locations; same great content:

Chicago, IL

Friday, February 13 (full day)

Houston, TX

Friday, February 20 (full day)

Orlando, FL

Friday, February 27 & Saturday, February 28 (half days)

www.asn-online.org/highlights



Blood Acidity

Continued from page 1

receptor function. What distinguishes this paper from previous work is that not only does it demonstrate an effect of extracellular pH on calcium-sensing receptor signaling and PTH release, but it demonstrates that in human parathyroid tissue, changes in extracellular pH within the physiologic range are capable of causing measurable changes in PTH secretion,” said R. Tyler Miller, MD, who was not involved in the study and is the vice chair of medicine at UT Southwestern Medical Center and

chief of medicine at the Dallas VA Medical Center. “The paper also demonstrates that the effect of pH is on the receptor, not the cells or other components of the experimental system.”
The calcium-sensing receptor is expressed in a variety of tissues and organs including the kidney, brain, intestine, bone, and skin where extracellular pH could also affect its function.
Miller noted that other work indicates that alterations in human pH that occur with kidney disease, high altitude, and possibly with diets of varying composition can alter metabolism, muscle mass, and bone structure, but the mechanisms for

these effects are unclear. Also, the physiologic effects of PTH are complicated and involve not just the level of PTH, but also the frequency of its release. “A long-term effect of pH on parathyroid function via PTH release is a reasonable possibility for some of the physiologic consequences of altered extracellular pH,” Miller said. “Precisely how PTH secretion is affected by extracellular pH will be interesting and valuable to learn as well as determining how pH and PTH secretion relate to long-term nutrition, body composition, and bone biology.”
Ward stressed that additional studies are needed before any clinical applications

might be realized. “Firstly, we would need to confirm that this effect is true not only in human cells in the laboratory, but also in live patients. However, if confirmed, then this might reveal a novel mechanism by which acidosis and bone mineral changes might be related in CKD patients,” he said. ●
Article: “Pathophysiologic Changes in Extracellular pH Modulate Parathyroid Calcium-Sensing Receptor Activity and Secretion via a Histidine-Independent Mechanism” <http://jasn.asnjournals.org/content/early/2015/01/01/ASN.2014070653.long>



INDICATION

AURYXIA is a phosphate binder indicated for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis.

IMPORTANT SAFETY INFORMATION

Contraindication: AURYXIA is contraindicated in patients with iron overload syndromes.

Iron Overload: Iron absorption from AURYXIA may lead to excessive elevations in iron stores. Assess iron parameters, serum ferritin and TSAT, prior to and while on AURYXIA. Patients receiving IV iron may require a reduction in dose or discontinuation of IV iron therapy.

Overdose: AURYXIA contains iron. Iron absorption from AURYXIA may lead to excessive elevations in iron stores, especially when concomitant IV iron is used.

Accidental Overdose of Iron: Accidental overdose of iron containing products is a leading cause of fatal poisoning in children under 6 years of age. Keep this product out of the reach of children.

Patients with Gastrointestinal Bleeding or Inflammation: Safety has not been established.

Pregnancy Category B and Nursing Mothers: Overdosing of iron in pregnant women may carry

Journal View

Patiromer Reduces Potassium in CKD Patients Taking RAAS Inhibitors

The new oral potassium binder patiromer effectively lowers serum potassium levels in patients with chronic kidney disease (CKD) who are being treated with renin-angiotensin-aldosterone system (RAAS) inhibitors, reports a trial in the *New England Journal of Medicine*.
The multicenter study included 243

patients with stage 3 or 4 CKD who were taking RAAS inhibitors and had a serum potassium level of 5.1 to less than 6.5 mmol/L. All received 4 weeks of treatment with patiromer. The starting dose was 4.2 or 8.4 g twice daily. Patients whose potassium level decreased to the target range (3.8 to less than 5.1 mmol/L) were eligible for an 8-week

randomized withdrawal phase, with one group continuing to receive patiromer and the other switching to placebo. Changes in potassium level were compared between groups.
The mean reduction in serum potassium during the initial treatment phase was 1.01 mmol/L, and 76 percent of patients reached the target range by 4

weeks. Among 107 patients enrolled in the withdrawal phase, potassium levels increased by 0.72 mmol/L within 4 weeks for those switching to placebo, compared with no change for those continuing to receive patiromer. The rates of recurrent hyperkalemia (potassium level 5.5 mmol/L or higher) were 60
Continued on page 8

For the control of serum phosphorus levels in patients with chronic kidney disease on dialysis

INTRODUCING AURYXIA (FERRIC CITRATE), THE FIRST AND ONLY ABSORBABLE-IRON-BASED PHOSPHATE BINDER CLINICALLY PROVEN TO MANAGE HYPERPHOSPHATEMIA¹⁻⁶

- Proven control of serum phosphorus within KDOQI guidelines (4.88 mg/dL at Week 56)^{7,8}
- Demonstrated safety and tolerability profile over 52 weeks
- Each AURYXIA tablet contains 210 mg ferric iron, equivalent to 1 g ferric citrate

Introducing
AuryxiaTM
(ferric citrate) tablets

References:
1. Fosrenol [package insert]. Wayne, PA: Shire US, Inc.; 2014. 2. Phoslyra [package insert]. Waltham, MA: Fresenius Medical Care North America; 2011. 3. PhosLo Gelcaps [package insert]. Waltham, MA: Fresenius Medical Care North America; 2012. 4. Renagel [package insert]. Cambridge, MA: Genzyme Corporation; 2014. 5. Renvela [package insert]. Cambridge, MA: Genzyme Corporation; 2014. 6. Velphoro [package insert]. Waltham, MA: Fresenius Medical Care North America; 2014. 7. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. *Am J Kidney Dis*. 2003;42(4 Suppl 3):S1-S201. 8. Data on File 1, Keryx Biopharmaceuticals, Inc.

a risk for spontaneous abortion, gestational diabetes, and fetal malformation. Rat studies have shown the transfer of iron into milk. There is possible infant exposure when AURYXIA is taken by a nursing woman.
Pediatric: The safety and efficacy of AURYXIA have not been established in pediatric patients.
Adverse Events: The most common adverse events with AURYXIA were diarrhea (21%), nausea (11%), constipation (8%), vomiting (7%), and cough (6%). Gastrointestinal adverse reactions were the most common reason for discontinuing AURYXIA (14%).

Drug Interactions: Doxycycline should be taken at least 1 hour before AURYXIA. Consider separation of the timing of the administration of AURYXIA with drugs where a reduction in their bioavailability would have a clinically significant effect on safety or efficacy.
Please see Brief Summary on following page.
You may report side effects to Keryx at 1-844-44KERYX (844-445-3799).

Journal View

Patriomer

Continued from page 1

percent versus 15 percent, respectively. During the initial treatment phase, mild to moderate constipation occurred in 11 percent of patients and hypokalemia in 3 percent.

Patiomer—a nonabsorbed polymer that binds potassium in exchange for calcium—was developed to meet the

need for effective outpatient treatments for hyperkalemia. This two-phase trial supports its effectiveness in reducing potassium levels and the rate of recurrent hyperkalemia in CKD patients taking RAAS inhibitors. Hypokalemia appears to be an infrequent and reversible event in patients taking patiomer [Weir MR, et al. Patiomer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. *N Engl J Med* doi: 10.1056/NEJMoa1410853]. ●

Longer Steroid Courses Don’t Affect Recurrence Rate in Nephrotic Syndrome

For children with steroid-sensitive nephrotic syndrome, extending initial steroid therapy from 3 to 6 months does not affect the subsequent relapse rate, reports a trial in *Kidney International*.

The randomized trial included 219 children with a first episode of steroid-sensitive nephrotic syndrome, enrolled at five academic hospitals in India. After 3

months of standard therapy with prednisolone, 181 children were assigned to receive 3 additional months of prednisone or 3 months of placebo therapy. The effects of extended steroid therapy on the risk of future relapse were assessed.

The cumulative initial prednisolone dosage was about 3500 mg/m² in the 6-month group versus 2800 mg/m² in the 3-month group. On intention-to-treat analysis, the numbers of steroid-sensitive relapses during the year after randomization were 1.26 and 1.54, respectively. The difference was not significant after adjustment for sex, age, and time to initial remission. The rates of sustained remission, frequent relapses, and adverse steroid effects were similar as well.

For children with idiopathic nephrotic syndrome, multiple relapses are associated with a risk of serious complications and medication-related adverse events. Some reports have suggested that a prolonged course of initial prednisolone therapy can reduce the relapse rate, although these studies have had important limitations.

The new trial finds no reduction in relapse rate for children with steroid-sensitive nephrotic syndrome assigned to 3 months versus 6 months of initial prednisolone therapy. Although extended treatment can postpone the occurrence of initial relapse, the 1-year relapse rates are similar between groups. A Japanese trial comparing 2 months versus 6 months of prednisolone, published in the same issue (*Kidney Int* 2015; 87:225–232), reaches a similar conclusion [Sinha A, et al. Extending initial prednisolone treatment in a randomized control trial from 3 to 6 months did not significantly influence the course of illness in children with steroid-sensitive nephrotic syndrome. *Kidney Int* 2015; 87:217–224]. ●

Surgical Robots Linked to Increased Rates of Partial Nephrectomy

Hospitals acquiring surgical robots are more likely to perform guideline-recommended partial nephrectomy in patients with renal cancer, reports a study in *Medical Care*.

The researchers used payer data from seven states to identify nearly 21,600 nephrectomies performed in 2001, 2005, and 2008. Hospital-level rates of partial nephrectomy were analyzed in relation to the hospitals’ acquisition of a surgical robotic system. The association was adjusted for nephrectomy volume, year of surgery, and other hospital factors.

Hospitals performed more partial nephrectomies after acquiring surgical robots. For hospitals acquiring robots between 2001 and 2004, the proportion of

AURYXIA™ (ferric citrate) tablets contain 210 mg of ferric iron equivalent to 1 g ferric citrate for oral use.

INDICATIONS AND USAGE

AURYXIA is a phosphate binder indicated for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis.

CONTRAINDICATIONS

AURYXIA is contraindicated in patients with iron overload syndromes (eg, hemochromatosis).

WARNINGS AND PRECAUTIONS

Iron Overload: Iron absorption from AURYXIA may lead to excessive elevations in iron stores. Increases in serum ferritin and transferrin saturation (TSAT) levels were observed in clinical trials. In a 56-week safety and efficacy trial in which concomitant use of AURYXIA and IV iron was permitted, 55 (19%) patients treated with AURYXIA had a ferritin level >1500 ng/mL as compared with 13 (9%) patients treated with active control. Assess iron parameters (eg, serum ferritin and TSAT) prior to initiating AURYXIA and monitor iron parameters while on therapy. Patients receiving IV iron may require a reduction in dose or discontinuation of IV iron therapy.

Accidental Overdose of Iron: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6 years of age. Keep this product out of the reach of children. In case of accidental overdose, call a doctor or poison control center immediately.

Patients with Gastrointestinal Bleeding or Inflammation: Patients with inflammatory bowel disease or active, symptomatic gastrointestinal bleeding were excluded from clinical trials. Safety has not been established in these populations.

ADVERSE REACTIONS

Adverse reactions to a drug are most readily ascertained by comparison with placebo, but there is little placebo-controlled experience with AURYXIA, so this section describes adverse events with AURYXIA, some of which may be disease-related, rather than treatment-related. A total of 289 patients were treated with AURYXIA and 149 patients were treated with active control (sevelamer carbonate and/or calcium acetate) during the 52-week, randomized, open-label, active control phase of a trial in patients on dialysis.

A total of 322 patients were treated with AURYXIA for up to 28 days in three short-term trials. Across these trials, 557 unique patients were treated with AURYXIA; dosage regimens in these trials ranged from 210 mg to 2,520 mg of ferric iron per day, equivalent to 1 to 12 tablets of AURYXIA. In these trials, adverse events reported for AURYXIA were similar to those reported for the active control group. Adverse events reported in more than 5% of patients treated with AURYXIA in these trials included diarrhea (21%), nausea (11%), constipation (8%), vomiting (7%), and cough (6%). During the 52-week active control period, 60 patients (21%) on AURYXIA discontinued study drug because of an adverse event, as compared to 21 patients (14%) in the active control arm. Patients who were previously intolerant to any of the active control treatments (calcium acetate and sevelamer carbonate) were not eligible to enroll in the study. Gastrointestinal adverse events were the most common reason for discontinuing AURYXIA (14%).

AURYXIA is associated with discolored feces (dark stools) related to the iron content, but this staining is not clinically relevant and does not affect laboratory tests for occult bleeding, which detect heme rather than non-heme iron in the stool.

DRUG INTERACTIONS

Doxycycline is an oral drug that has to be taken at least 1 hour before AURYXIA. Oral drugs that can be administered concomitantly with AURYXIA are: amlodipine, aspirin, atorvastatin, calcitriol, clopidogrel, digoxin, doxercalciferol, enalapril, fluvastatin, levofloxacin, metoprolol, pravastatin, propranolol, sitagliptin, and warfarin. There are no empirical data on avoiding drug interactions between AURYXIA and most concomitant oral drugs. For oral medications where a reduction in the bioavailability of that medication would have a clinically significant effect on its safety or efficacy, consider separation of the timing of the administration of the two drugs. The duration of separation depends upon the absorption characteristics of the medication concomitantly administered, such as the time to reach peak systemic levels and whether the drug is an immediate release or an extended release product. Consider monitoring clinical responses or blood levels of concomitant medications that have a narrow therapeutic range.

USE IN SPECIFIC POPULATIONS

Pregnancy: Pregnancy Category B: There are no adequate and well-controlled studies in pregnant women. It is not known whether AURYXIA can cause fetal harm when administered to a pregnant woman. Animal reproduction studies have not been conducted.

The effect of AURYXIA on the absorption of vitamins and other nutrients has not been studied in pregnant women. Requirements for vitamins and other nutrients are increased in pregnancy. An overdose of iron in pregnant women may carry a risk for spontaneous abortion, gestational diabetes, and fetal malformation.

Labor and Delivery: The effects of AURYXIA on labor and delivery are unknown.

Nursing Mothers: Data from rat studies have shown the transfer of iron into milk by divalent metal transporter-1 (DMT-1) and ferroportin-1 (FPN-1). Hence, there is a possibility of infant exposure when AURYXIA is administered to a nursing woman.

Pediatric Use: The safety and efficacy of AURYXIA have not been established in pediatric patients.

Geriatric Use: Clinical studies of AURYXIA included 106 subjects aged 65 years and older (33 subjects aged 75 years and older). Overall, the clinical study experience has not identified any obvious differences in responses between the elderly and younger patients in the tolerability or efficacy of AURYXIA.

OVERDOSAGE

No data are available regarding overdose of AURYXIA in patients. In patients with chronic kidney disease on dialysis, the maximum dose studied was 2,520 mg ferric iron (12 tablets of AURYXIA) per day. Iron absorption from AURYXIA may lead to excessive elevations in iron stores, especially when concomitant IV iron is used.

In clinical trials, one case of elevated iron in the liver as confirmed by biopsy was reported in a patient administered IV iron and AURYXIA.


PATIENT COUNSELING INFORMATION

Dosing Recommendations: Inform patients to take AURYXIA as directed with meals and adhere to their prescribed diets. Instruct patients on concomitant medications that should be dosed apart from AURYXIA.

Adverse Reactions: Advise patients that AURYXIA may cause discolored (dark) stools, but this staining of the stool is considered normal with oral medications containing iron.

AURYXIA may cause diarrhea, nausea, constipation, and vomiting. Advise patients to report severe or persistent gastrointestinal symptoms to their physician.

Keryx Biopharmaceuticals, Inc.
©2014 Keryx Biopharmaceuticals, Inc.



HeRO Graft bypasses central venous stenosis



HeRO (Hemodialysis Reliable OutFlow) Graft is the **ONLY** fully subcutaneous AV access solution clinically proven to maintain long-term access for hemodialysis patients with **central venous stenosis**.

- **Fewer Infections:** 69% reduced infection rate compared with catheters¹
- **Superior Dialysis Adequacy:** 1.7 Kt/V, a 16% to 32% improvement compared with catheters¹
- **High Patency Rates:** Up to 87% cumulative patency at 2 years^{1, 2}
- **Cost Savings:** A 23% average savings per year compared with catheters³

Reducing Catheter Dependency

HeRO Graft Candidates

- Catheter-dependent or approaching catheter-dependency
- Failing AVF or AVG due to central venous stenosis

Treatment Algorithm

Failing AVF or AVG due to **central venous stenosis**



Catheter-dependent patients

Learn more at www.herograft.com

Order at: **888.427.9654**

References:

1) Katzman et al., J Vasc Surg 2009. 2) Gage et al., EJVES 2012. 3) Dageforde et al., JSR 2012.

Indications for Use: The HeRO Graft is indicated for end stage renal disease patients on hemodialysis who have exhausted all other access options. See Instructions for Use for full indication, contraindication and caution statements. Rx only.

HeRO Graft is classified by the FDA as a vascular graft prosthesis.

1655 Roberts Boulevard, NW • Kennesaw, Georgia 30144 • Phone (888) 427-9654 • (770) 419-3355
All trademarks are owned by CryoLife, Inc. or its subsidiaries. HeRO Graft is a Hemosphere, Inc. product distributed by CryoLife, Inc. and Hemosphere, Inc. © 2012 CryoLife, Inc. All rights reserved.



1. Download the App
2. Scan the code with your mobile device to watch video

Get the free mobile app at
<http://gettag.mobi>

 **CryoLife**[®]
Life Restoring Technologies[®]

Journal View

Surgical Robots

Continued from page 8

partial nephrectomies increased by about 30 percent in 2005 and 35 percent in 2008. A smaller increase of 15.5 percent was noted for hospitals acquiring a surgical robot between 2005 and 2008.

Hospitals with a higher nephrectomy volume and those in urban locations had higher rates of partial nephrectomy. At hospitals that had not acquired a robotic system by 2008, partial nephrectomy was performed in just 20 percent of cases.

Nephron-sparing surgery is a guideline-supported but underused alterna-

tive to radical nephrectomy for patients with renal cancer. The new analysis suggests that surgical robots—a costly and controversial use of technology—facilitate the performance of partial nephrectomy in this group of patients.

“This is one of the few studies to suggest robot acquisition is associated with improvement in quality of patient care,”

the researchers write. They discuss the implications for adoption of new technologies, noting that the “earliest adopters” of surgical robots had the greatest increases in partial nephrectomy [Sivara-jan G, et al. The effect of the diffusion of the surgical robot on the hospital-level utilization of partial nephrectomy. *Med Care* 2015; 53:71–78]. ●

Is Metformin Safe for Patients with Kidney Disease?

Available data support the “cautious expansion” of metformin use for patients with type 2 diabetes and mild to moderate chronic kidney disease (CKD), according to a systematic review in the *Journal of the American Medical Association*.

A literature search identified 65 publications providing data on the risk of lactic acidosis in metformin-treated patients with impaired renal function. Since its approval in 1994, metformin has been contraindi-

cated for use in patients with “renal disease or renal dysfunction.”

However, the evidence suggested that drug levels generally remained in the therapeutic range for metformin-treated patients with mild to moderate CKD (estimated GFR 30 to 60 mL/min/1.73 m²). Despite renal clearance of metformin, the rates of lactic acidosis were low and in the range of the background rate among all patients with diabetes: about three to ten cases per

100,000 person-years.

There were no randomized trials evaluating the safety of metformin in patients with impaired kidney function. Some reports suggested that the guidelines regarding metformin use in kidney disease are “commonly disregarded,” with no increase in adverse events. Observational studies suggested beneficial effects on macrovascular outcomes, even in patients with contraindications to metformin use.

On the basis of these data, the authors suggest a change in prescribing guidelines to permit metformin use in patients with mild to moderate CKD. They emphasize that any such strategy would require appropriate dosage reductions and careful monitoring of kidney function [Inzucchi SE, et al. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. *JAMA* 2014; 312: 2668–2675]. ●

Kidney Transplantation Practice Improvement Module

New!



Earn 20 MOC points from ABIM

The Kidney Transplantation PIM has been planned and implemented through the joint providership of American Society of Nephrology (ASN) and American Society of Transplantation (AST). The program was designed to help you improve care for post-kidney transplant patients.

Meaningfully improve patient care

- Assess & evaluate current practice performance
- Identify areas for improvement
- Develop individual or practice-wide improvement plan
- Remeasure performance
- See and compare improvements over time

To learn more, visit asn-online.org/pim



Industry Spotlight

NephroCheck Test Gauges Risk for AKI

The NephroCheck test system is now being marketed by Ortho Clinical Diagnostics to help identify risk of acute kidney injury (AKI). The urine test is designed to detect both insulin-like growth factor binding protein 7 and tissue inhibitor of metalloproteinases, factors associated with AKI.

The test provides a score within 20 minutes that shows a patient's risk for the development of AKI, Ortho noted in an announcement. Patients with a positive NephroCheck risk (greater than the defined cutoff point of 0.3) have a one-

in-four to a one-in-three chance of developing moderate or severe AKI within 12 hours of assessment, Ortho reported.

The U.S. Food and Drug Administration (FDA) approved the test, manufactured by Astute Medical, in September 2014.

The test has shown that it gives a positive result in about half of patients who do not have AKI, according to Medscape. Two studies compared NephroCheck results with the diagnoses in more than 500 critically ill patients at 23 hospitals; the test accurately detected 92 percent of AKI patients in

one study and 76 percent in the other.

The test system may be used along with clinical evaluation in intensive care unit patients who currently have or have had within the preceding 24 hours an acute cardiovascular event, respiratory compromise, or both. The test should be used as an aid in the risk assessment for moderate or severe AKI within 12 hours of patient assessment in patients over age 21.

For more information about the product, visit www.astutemedical.com.

New Combo Drug for Hypertension

For the first time, the U.S. Food and Drug Administration (FDA) has approved a fixed-dose antihypertensive pill combining angiotensin-converting enzyme inhibitor and beta blocker compounds. The drug, brand name Prestalia (Symplmed, Cincinnati, Ohio), contains perindopril arginine, an angiotensin-converting enzyme inhibitor, and amlodipine, a dihydropyridine calcium channel blocker.

Symplmed says Prestalia is intended for patients who fail to lower blood pressure with a single drug. Thus the drug may be used as a first-line therapy in patients likely to need multiple drugs to achieve blood pressure goals.

The FDA approved the drug based on phase III data from the 837-patient PATH trial (Perindopril Amlodipine for the Treatment of Hypertension trial), which demonstrated that the fixed-dose combination in one pill was more effective than either compound taken alone for reducing sitting diastolic and sitting systolic blood pressure after six weeks of treatment.

Both drugs alone can cause hypotension, and perindopril can cause swelling of the head and neck. Warnings include not giving diabetic patients aliskiren (a renin inhibitor for primary hypertension) along with ACE inhibitors, including Prestalia, as well as discon-

tinuing Prestalia immediately when a patient learns she is pregnant.

The company has several other combination drugs for hypertension in the pipeline, all containing perindopril perindopril plus atorvastatin, perindopril plus indapamide, and perindopril plus amlodipine (the two drugs in Prestalia) plus indapamide. Its first product, perindopril erbumine (Aceon), is an antihypertensive drug that can be taken alone or in combination with other classes of hypertension-reducing drugs. Aceon is used to treat patients with high blood pressure and to reduce the risk of heart attack.

Report Details Nephrology Fellow Demographics, Job Market Concerns

By Kurtis Pivert

ASN's latest nephrology workforce report provides a detailed portrait of future nephrologists and their perceptions of, and experiences in, the current job market. *Findings from the 2014 Survey of Nephrology Fellows* is the second in a series of workforce studies authored by George Washington University (GWU) investigators. The analysis of the 2014 ASN Nephrology Fellow Survey provides clues about demand for the specialty and a baseline for future research.

The report confirms recent trends in nephrology training. International medical graduates (IMGs) comprised the majority of respondents (64 percent), reflecting the continued decline in the number of US medical graduates (USMGs) choosing the specialty. Despite an increase in women entering nephrology, most of the 1st and 2nd year fellows who answered the survey were men (61 percent). Fellows' racial and ethnic composition remains unrepresentative of the communities they will serve—only 9 percent of fellow respondents were African American and 8 percent Hispanic.

Distributed to ASN fellow members in June 2014, the survey is an important component of ASN's ongoing collaboration with GWU to study all aspects of the specialty. Workforce research is one of ASN's many initiatives to increase interest in nephrology careers. Although this initial survey elicited a low

response rate (35.8 percent), the participants' demographic characteristics were similar to those of all nephrology fellows, according to information from the Accreditation Council for Graduate Medical Education database.

"This kind of survey can provide a good picture of the future supply," said lead author Edward Salsberg, MPA. "The experience of new entrants into the job market can also provide a valuable snapshot of the regional and national demand."

Job search experiences and market perceptions differed between IMGs and USMGs. IMGs were more likely to practice in a Health Professional Shortage Area and to report difficulties in finding a satisfactory position. USMGs were more likely to note a lack of jobs in desired locations and to perceive more job opportunities nationally than locally.

A substantial proportion of nephrology fellows looking for employment reported changing their plans because of limited practice opportunities (43 percent). Although nephrology fellows' perceptions of local job opportunities (within 50 miles of their training site) were disappointing (71 percent said there were no, very few, or few nephrology practice opportunities), a vast majority indicated they would still recommend the specialty to medical students and residents (72 percent).

The report's release extended a continuing dialogue among the kidney community that started with the disappointing nephrology Match for academic year 2015–2016, which has expanded to social media. An ongoing discussion of the report, the Match, and nephrology careers on Twitter—at the #NephWorkforce hashtag—has explored many themes. These include the hurdles IMGs encounter in locating employment and research funding, student debt, and the importance of mentorship. ASN encourages all stakeholders to join this discussion using the #NephWorkforce hashtag.

Salsberg, together with Principal Investigator Leah Masselink, PhD, will focus future reports on the effects of changes in care delivery on the specialty, as well as geographic distribution of practicing nephrologists and training programs.

As of press time, ASN announced the Nephrology Match Task Force will be chaired by ASN President-Elect Raymond C. Harris, MD, FASN. Composed of Nephrology Training Program Directors, Division Chiefs, and ASN Councilors, the task force will address issues surrounding the Match, including an assessment of its future viability and identifying ways to ensure its integrity.

The nephrology fellow survey report is available at <http://www.asn-online.org/education/training/workforce/>.

ABIM Announces Changes to MOC Program

Responding to concerns raised by ASN, the American College of Physicians, and other medical specialty societies, the American Board of Internal Medicine (ABIM) on February 3, 2015, announced it is suspending the Practice Assessment, Patient Voice, and Patient Safety requirements of its Maintenance of Certification (MOC) program for at least 2 years in order to engage the medical community's input regarding its MOC program.

Starting a year ago, ABIM changed its once-every-10-years MOC program to a more continuous one. The change generated substantial criticism among internists and medical specialties.

"Some believe ABIM has turned a deaf ear to practicing physicians and has not adequately developed a relevant, meaningful program for them as they strive to keep up to date in their fields," ABIM President and CEO Richard Baron, MD, MACP, said in a statement. "ABIM clearly got it wrong. We launched programs that weren't ready and we didn't deliver an MOC program that physi-

cians found meaningful. We want to change that."

ABIM plans to institute the following changes:

- Within the next 6 months, ABIM will change the language used to publicly report a diplomate's MOC status on its website from "meeting MOC requirements" to "participating in MOC."
- ABIM is updating the Internal Medicine MOC exam. The update will focus on making the exam more reflective of what physicians in practice are doing, with any changes to be incorporated beginning fall 2015. More subspecialty MOC exams will follow.
- MOC enrollment fees will remain at or below the 2014 levels through at least 2017.
- By the end of 2015, ABIM will assure new and more flexible ways for internists to demonstrate self-assessment of medical knowledge by recog-

nizing most forms of continuing medical education approved by the Accreditation Council for Continuing Medical Education.

- Effective immediately, ABIM is suspending the Practice Assessment, Patient Voice, and Patient Safety requirements for at least 2 years. This means that no internist will have his or her certification status changed for not having completed activities in these areas for at least the next 2 years. Diplomates who are currently not certified but who have satisfied all requirements for MOC except for the Practice Assessment requirement will be issued a new certificate this year.

The organization plans to work with medical societies and directly with diplomates to seek input regarding the MOC program through meetings, webinars, forums, online communications channels, and surveys. For more information, please see the ABIM MOC FAQ page. ●

KIDNEYWEEK²⁰¹⁴

Philadelphia, PA • Nov 11 - 16

ON-DEMANDTM

Kidney Week On-Demand: online access to more than 350 hours of educational content from the meeting. This resource in the ASN Learning Center is complimentary to fully paid Annual Meeting participants with access codes or is available for purchase.

For more information on sessions captured or how to purchase, visit www.asn-online.org/dl/kw.

CME credit will not be awarded for these materials.

Detective Nephron

Detective Nephron, world-renowned for his expert analytic skills, trains budding physician-detectives in the diagnosis and treatment of kidney diseases. L.O. Henle, a budding nephrologist, presents a new case to the master consultant.



Mr. Mac Uladensa, a visiting medical student, enters the room along with L.O. Henle to present a case.

Nephron *(with surprise)*: My apprentice, what do you have for me? And who do we have here?

Henle and Mac look at each other.

Henle This is Mac, a visiting medical student, here to learn about nephrology.

Nephron *(with a smile)*: Glad to have you on board. Nephrology is a fun field of medicine and probably the most enigmatic. There is a lot of physiology, pharmacology, and pathology to learn in nephrology. The kidney is a smart organ!

Mac Glad to be on board. I just played NephMadness online and learned a lot of fun facts about nephrology.

Henle We have a case of a bicarbonate level of 60 mEq/L.

Nephron The patient is likely vomiting. What do you want me to do?

Mac The arterial blood gas determination shows a pH of 7.60 and pCO₂ of 66 mm Hg. Serum chloride is 68 mEq/L.

Henle So the patient has a metabolic alkalosis with good compensation.

Nephron I am still confused. Why are you presenting this to me? This sounds like a case of vomiting with some degree of volume depletion leading to metabolic alkalosis.

Mac Why is the urinary sodium not lower than 10 mEq/L? It is 45 mEq/L.

Nephron *(happy)*: Ah! There is an interesting and commonly asked question, but poorly understood. Let's start from the basics. What happens during vomiting?

Mac Vomiting removes gastric fluid from the stomach, although the parietal cells in the stomach still continue to produce hydrogen ions and release bicarbonate into the blood. Because this bicarbonate is not neutralized, this generates metabolic alkalosis.

Nephron What happens in the kidney?

Mac There is increased filtration of this bicarbonate, and it meets the proximal tubule. Given that there is no need to reabsorb this bicarbonate, it will just get excreted.

Henle But doesn't it need a cation to get excreted with?

Mac *(with a smile)*: Likely sodium....hence making urinary sodium high in the state of vomiting.

Nephron Good work, my friends. Normally, in the absence of volume

depletion, metabolic alkalosis is corrected by the excretion of excess bicarbonate in the urine. To maintain electroneutrality, sodium gets excreted in the urine. But what do you think happens when there is volume depletion?

Mac Hmm, does volume trump everything?

Nephron What is this patient's urinary pH? It has to be alkalemic.

Henle Suggesting loss of bicarbonate and hence urine sodium being high.

Nephron *(with a wink)*: Now let's assume this patient's systolic blood pressure drops because of excessive vomiting. What happens then?

Henle A tug of war between metabolic alkalosis and volume. There might be times when sodium will be taken back to maintain blood pressure but can fluctuate. Volume will win most of the time. So, if volume rules, the reabsorption of sodium with bicarbonate continues and maintains the metabolic alkalosis.

Nephron Bingo! Not only have you explained that volume trumps everything, but also you have mentioned one of the key components that maintains metabolic alkalosis, which is hypovolemia. So vomiting in this case is generating and maintaining metabolic alkalosis.

Henle Let's get back to our patient. So does urinary chloride help us in this situation?

Nephron The spot urine chloride is always appropriately low: below 20 mEq/L in metabolic alkalosis because of vomiting, and that can help in the diagnosis. The spot urine sodium might be low if the patient is in a volume-depleted state, or it can fluctuate as you mentioned, based on who is winning: volume or alkalemia. But the urine chloride will be low.

Let me ask you, then: what else will maintain this metabolic alkalosis besides the hypovolemia?

Mac *(confidently)*: Well, low volume will maintain it by stimulating aldosterone, and excess mineralocorticoid activity would then be the second way to maintain it. Aldosterone will enhance the activity of the H⁺-ATPase pumps in the intercalated cells and lead to reabsorption of bicarbonate. Aldosterone also increases sodium absorption in the principal cells, leaving the lumen negatively charged, promoting hydrogen ion secretion leading to bicarbonate generation.

Nephron Good points. Anything else that maintains this?

Henle *(jumping in)*: Chloride depletion itself in this vomiting state will lead to maintaining the alkalosis. In type A intercalated cells, there is a Cl/HCO₃⁻ exchanger in the basolateral membrane. If there is less chloride in the lumen, there is loss of chloride and hydrogen secretion, leading to bicarbonate reabsorption. In addition, in the

Continued on page 14

Detective Nephron

Continued from page 13

type B intercalated cells, the Cl/HCO_3^- exchanger is in the luminal side, leading bicarbonate to be retained and not secreted because chloride in the tubular flow is low.

Nephron Sounds as if you know most of this very well. Good work, Henle. This is an important concept to understand.

Mac (*interrupting*): I think the last factor would be hypokalemia. This is partly due to aldosterone again. The distal nephron hydrogen secretion is stimulated by the low potassium state, leading to increased bicarbonate generation.

Nephron Also, NH_4^+ is made from glutamine in the proximal tubule. The latter is unregulated in hypokalemia. NH_4^+ is excreted in the lumen (trapped). Therefore, HCO_3^- is reabsorbed. This is an additional mechanism.

Henle Now, back to our patient. As we know, this patient has active metabolic alkalosis. But the team is puzzled about the cause of this?

Nephron (*with a bored face*): Why are they so puzzled?

Mac (*scared*): Did we mention to you that the patient has ESRD and is receiving hemodialysis?

Nephron (*with a surprised look*): Ahhh! So now you tell me, after that long discussion regarding urinary losses and urinary bicarbonate generation and so forth, that there is not much urine!

Mac Affirmative.

Nephron Well, that whole discussion is off the table, then, because this patient makes no urine. Am I repeating myself?

Mac Affirmative.

Nephron Nothing gets a nephrologist more excited than seeing metabolic alkalosis in a dialysis patient, because it's not the usual situation.

Henle (*jumping in*): In a dialysis patient, the increase in serum bicarbonate concentration can be caused only by metabolic alkalosis. Primary respiratory acidosis with compensatory metabolic alkalosis cannot be possible because there is no kidney function.

Nephron Good point—and in this case, it doesn't matter that the urine sodium was 45 mEq/L, because overall the patient doesn't make that much urine.

Henle Also, given that the patient has no kidney function, metabolic alkalosis can occur only if there was excess alkali intake or significant hydrogen ion loss.

Mac So in this case, we don't need to consider mineralocorticoid excess and or other urinary transport problems?

Nephron (*with a smirk*): Affirmative.

Mac So this has to be a gastrointestinal loss? Should we image the abdomen?

Nephron I would. This could be as simple as a "bad" ulcer or a gastrointestinal outlet obstruction or increased gastrin production producing a tumor?

Mac When we lose hydrogen ion in emesis, how much bicarbonate gets generated?

Nephron One millimole of bicarbonate is generated in body fluids for each millimole of hydrogen ion lost in emesis—although this added alkali is buffered, but given that this patient has no kidney function, the increased bicarbonate is sustained.

Henle and Mac exit to order the suggested tests.

A day later:

Henle A computed tomographic scan revealed a gastric mass, and a biopsy was performed. Hemodialysis was initiated with the goal of helping decrease the alkalosis.

Nephron Isotonic fluids may restore the volume loss here, and it may dilute the body's alkali stores, but it will not correct alkalosis because no bicarbonate excretion is happening. Hence, hemodialysis with a reduced bicarbonate bath is a safe and effective treatment.

Henle and Mac exit to order the suggested tests.

A day later:

Nephron What do we have as the final diagnosis?

Mac A gastrinoma.

Henle The patient was also prescribed a proton pump inhibitor. His electrolytes normalized, and currently he is awaiting evaluation by the hematology and oncology services.

Nephron Mac and Henle, you have stumped me this time with an excellent case of alkalosis in a dialysis patient. Again, nephrologists can always be amazing detectives. With one electrolyte disorder in a patient with ESRD, you made a systemic diagnosis! The problem is not always in the kidney! Let's have some coffee to celebrate! ●

Detective Nephron was developed by Kenar Jhaveri, MD, associate professor of medicine at Hofstra North Shore LIJ School of Medicine. Thanks to Dr. Rimda Wanchoo, assistant professor of medicine at Hofstra North Shore LIJ School of Medicine, for her editorial assistance.



Classified Ads

PRINT ADVERTISING
THE EFFECTIVE WAY TO:

- GROW YOUR WORKFORCE
- INVEST IN YOUR FUTURE WITH FELLOWSHIPS
- FURTHER YOUR EDUCATION WITH CME COURSES
- PROMOTE AN UPCOMING CONFERENCE

These plus more opportunities available when you contact

Rhonda Truitt
rhonda.truitt@wt-group.com
443-512-8899 x 106

Kidney News
Classified Advertising Information

Classified space is for advertising positions available, open faculty positions, course announcements, seminars, meetings and educational courses.

Display Advertising Rates

Ad Size	1x	3x
Full Page	\$2,525	\$2,345
1/2 Page	\$1,665	\$1,485
1/3 Page	\$1,435	\$1,375
1/4 Page	\$1,205	\$1,090
1/6 Page	\$1,035	\$1,025

Line Advertising Rates

Please contact for rate information

Closing Date & Cancellations:

Copy must be received four weeks in advance of the month in which the ad is to appear. Cancellation requests must be made in written form by fax, e-mail or postal mail and will be honored for the earliest applicable issue.

ALL ADS
MUST BE PREPAID

Contact:

Rhonda Truitt
rhonda.truitt@wt-group.com
P: 443-512-8899 x. 106 F: 443-512-8909

High School Student Develops Noninvasive Screening Tool for Chronic Kidney Transplant Rejection

Kidney transplantation has been the preferred treatment for people suffering from kidney failure since Dr. Joseph E. Murray completed the first successful kidney transplant in 1954. Although recent advances in transplant medicine have drastically lowered the risk of acute transplant rejection, these advances have failed to deliver an effective treatment for chronic allograft nephropathy (CAN), which remains the leading cause of organ loss following transplantation and limits the 10-year survival rate of a kidney transplant to 54%. If detected early, intervention can minimize CAN, but the current “gold standard” for diagnosis is tissue biopsy, which is heavily invasive and cannot detect the disease

until after substantial kidney damage has already occurred. For Demetri Maxim, a high school junior in Maine, the difficulties of kidney transplants and kidney disease are personal. In August 2004, Demetri’s mother, Lefki, lost both her kidneys to polycystic kidney disease (PKD) and was forced to go on dialysis. Fortunately, she received a kidney transplant in October 2005, just 14 months later. Demetri also has PKD and may someday lose his kidney function as well. Demetri’s mother experienced four different rejection episodes in the first 18 months of her transplant. Each episode necessitated a painful biopsy that involved removing a small piece of the

kidney to test for rejection, a process that further reduces the long-term success of the organ. Demetri knew there had to be another way to tell whether or not she was rejecting her kidney. So the summer before he started high school he set out to invent an alternative method of detecting CAN. Two years later, in March 2014, following countless hours of background research and lab work, Demetri’s invention won grand prize at the Maine State High School Science Fair and qualified for the Intel International Science and Engineering Fair. At Kidney Week 2014, Demetri presented a poster describing the simple, portable, patent-pending device that can be used to non-invasively monitor

CAN in kidney transplant recipients. The device works by screening patient blood samples for the biomarker VEGF-C, which is upregulated during CAN. The device is 11 times faster and 16 times less expensive than the current gold standard for biomarker detection, ELISA. He hopes to publish his work. Demetri currently works in Dr. Joseph Bonventre’s Laboratory of Kidney Injury and Repair at the Brigham and Women’s Hospital and Harvard Medical School on research to bioengineer an artificial kidney. He plans to continue this work and pursue pre-med studies to ultimately become a nephrologist and lead the fight against kidney disease in the next generation. ●

Index to Advertisers

AstraZeneca	Pages 2-3
CryoLife	Page 9
Keryx	Pages 6-8
Spectra	Back Page



Time out.

Let's take a moment to look at the current state of the lab industry.

These days, a lot of labs are stripping away all of their value-added services and support to bring you that “unbelievably low” price. **At Spectra we believe the best price is one that doesn't come at a sacrifice to the quality of your results, efficiency of your staff, or the care of your patients.** We offer everything for one fair price—customer service, education and training, couriers, and medically necessary testing with no arbitrary limitations.

We're proud to have maintained our core business values to provide all the resources that are in the best interest of your staff and your patients.

www.spectra-labs.com

